Keywords
Last Name
Institution

JOHN MOORE VIERLING

TitleProfessor
InstitutionBaylor College of Medicine
DepartmentDepartment of Surgery
DivisionSurgery-Transplant Division
Address6620 Main Stree, Suite 1425
Houston TX 77030
vCardDownload vCard
    Other Positions
    TitleProfessor
    InstitutionBaylor College of Medicine
    DepartmentDepartment of Medicine
    DivisionMedicine-Gastroenterology & Hepatol


    Collapse Additional Tools and Researcher Information 
    Collapse Verify Publications

    Collapse Overview 
    Collapse overview
    Dr. John M. Vierling’s primary research interests are the immunopathogenic mechanisms involved in hepatobiliary injury caused by viral infection, autoimmunity, alloimmunity, and non-alcoholic fatty liver disease. Dr. Vierling’s basic science laboratory investigations have used murine models to study the immunopathogenesis of non-suppurative destructive cholangitis, which destroys bile ducts in primary biliary cirrhosis, an autoimmune liver disease, as well as in two alloimmune diseases, hepatic allograft rejection and chronic graft-versus-host disease.

    By emphasizing a "laboratory bench to bedside" philosophy, Dr. Vierling has also been active in the design and execution of clinical therapeutic trials of antiviral agents for treatment of hepatitis B and C infections in patients before and after liver transplantation, trials of immunosuppressive drugs in liver transplantation and autoimmune liver diseases, trials of new therapies for hepatic encephalopathy and antifibrotic agents to prevent or reverse cirrhosis. Dr. Vierling is the author of numerous research publications, reviews and chapters on these topics.

    Dr. Vierling directs Advanced Liver Therapies, a clinical research unit devoted to hepatobiliary diseases. He and his research staff are conducting phase 1-3 studies of diagnostics and therapies in chronic hepatitis B, chronic hepatitis C, primary biliary cirrhosis, non-alcoholic fatty liver disease, anti-fibrotic therapy to prevent cirrhosis, hepatic encephalopathy, and measurement of hepatocellular function using 13C-labeled compounds.

    Dr. Vierling is board certified in internal medicine and gastroenterology and a Fellow of the American College of Physicians. He created a liver transplant program at the University of olorado Health Sciences Center.

    Collapse keywords
    • Acute liver failure
    • Alcoholic and non-alcoholic fatty liver diseases
    • Alpha-1-antitrypsin deficiency
    • Autoimmune hepatitis
    • Cholangocarcinoma
    • Cirrhosis
    • Clinical therapeutic trials
    • Drug-induced liver injury
    • Gastroesophageal varices
    • Genetic and metabolic diseases
    • Hemochromatosis
    • Hepatic encephalopathy pre and post liver transplantation care
    • Hepatocellular carcinoma
    • Primary biliary cirrhosis
    • Primary sclerosing cholangitis
    • Viral hepatitis
    • Wilson's disease


    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Bourlière M, Gordon SC, Flamm SL, Cooper CL, Ramji A, Tong M, Ravendhran N, Vierling JM, Tran TT, Pianko S, Bansal MB, de Lédinghen V, Hyland RH, Stamm LM, Dvory-Sobol H, Svarovskaia E, Zhang J, Huang KC, Subramanian GM, Brainard DM, McHutchison JG, Verna EC, Buggisch P, Landis CS, Younes ZH, Curry MP, Strasser SI, Schiff ER, Reddy KR, Manns MP, Kowdley KV, Zeuzem S. Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection. N Engl J Med. 2017 06 01; 376(22):2134-2146. PMID: 28564569.
      View in: PubMed
    2. Goss M, Reese J, Kueht M, Vierling JM, Mindikoglu AL, Sussman NL, Kaplan B, Wood RP, Rana AA. A Surge in Cadaveric Liver Donors and a National Narcotic Epidemic: Is There an Association? Liver Transpl. 2017 Mar 14. PMID: 28295986.
      View in: PubMed
    3. Liberal R, de Boer YS, Andrade RJ, Bouma G, Dalekos GN, Floreani A, Gleeson D, Hirschfield GM, Invernizzi P, Lenzi M, Lohse AW, Macedo G, Milkiewicz P, Terziroli B, van Hoek B, Vierling JM, Heneghan MA. Expert clinical management of autoimmune hepatitis in the real world. Aliment Pharmacol Ther. 2016 Dec 22. PMID: 28004405.
      View in: PubMed
    4. Rodriguez-Torres M, Lawitz E, Yangco B, Jeffers L, Han SH, Thuluvath PJ, Rustgi V, Harrison S, Ghalib R, Vierling JM, Luketic V, Zamor PJ, Ravendhran N, Morgan TR, Pearlman B, O'Brien C, Khallafi H, Pyrsopoulos N, Kong G, McPhee F, Yin PD, Hughes E, Treitel M. Daclatasvir and Peginterferon/Ribavirin for Black/African-American and Latino Patients with HCV infection. Ann Hepatol. 2016 Nov-Dec 2016; 15(6):834-845. PMID: 27740516.
      View in: PubMed
    5. Kwo P, Gane E, Peng CY, Pearlman B, Vierling JM, Serfaty L, Buti M, Shafran S, Stryszak P, Lin L, Gress J, Black S, Dutko FJ, Robertson M, Wahl J, Lupinacci L, Barr E, Haber B. Effectiveness of Elbasvir and Grazoprevir Combination, With or Without Ribavirin, for Treatment-Experienced Patients with Chronic Hepatitis C Infection. Gastroenterology. 2016 Oct 5. PMID: 27720838.
      View in: PubMed
    6. Tanaka A, Ma X, Yokosuka O, Weltman M, You H, Amarapurkar DN, Kim YJ, Abbas Z, Payawal DA, Chang ML, Efe C, Ozaslan E, Abe M, Mitchell-Thain R, Zeniya M, Han KH, Vierling JM, Takikawa H. Autoimmune liver diseases in the Asia-Pacific region: Proceedings of APASL symposium on AIH and PBC 2016. Hepatol Int. 2016 Nov; 10(6):909-915. PMID: 27649967.
      View in: PubMed
    7. Foster GR, Chayama K, Chuang WL, Fainboim H, Farkkila M, Gadano A, Gaeta GB, Hézode C, Inada Y, Heo J, Kumada H, Lu SN, Marcellin P, Moreno C, Roberts SK, Strasser SI, Thompson AJ, Toyota J, Paik SW, Vierling JM, Zignego AL, Cohen D, McPhee F, Wind-Rotolo M, Srinivasan S, Hruska M, Myler H, Portsmouth SD. A randomized, controlled study of peginterferon lambda-1a/ribavirin ± daclatasvir for hepatitis C virus genotype 2 or 3. Springerplus. 2016; 5(1):1365. PMID: 27588258; PMCID: PMC4990525.
    8. Liberal R, Krawitt EL, Vierling JM, Manns MP, Mieli-Vergani G, Vergani D. Cutting edge issues in autoimmune hepatitis. J Autoimmun. 2016 Dec; 75:6-19. PMID: 27502148.
      View in: PubMed
    9. Poordad F, Schiff ER, Vierling JM, Landis C, Fontana RJ, Yang R, McPhee F, Hughes EA, Noviello S, Swenson ES. Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence. Hepatology. 2016 May; 63(5):1493-505. PMID: 26754432.
      View in: PubMed
    10. Landis CS, Ghabril M, Rustgi V, Di Bisceglie AM, Maliakkal B, Rockey DC, Vierling JM, Bajaj J, Rowell R, Santoro M, Enriquez A, Jurek M, Mokhtarani M, Coakley DF, Scharschmidt BF. Prospective Multicenter Observational Study of Overt Hepatic Encephalopathy. Dig Dis Sci. 2016 Jun; 61(6):1728-34. PMID: 26781427.
      View in: PubMed
    11. Beuers U, Gershwin ME, Gish RG, Invernizzi P, Jones DE, Lindor K, Ma X, Mackay IR, Parés A, Tanaka A, Vierling JM, Poupon R. Changing nomenclature for PBC: From 'cirrhosis' to 'cholangitis'. Clin Res Hepatol Gastroenterol. 2015 Oct; 39(5):e57-9. PMID: 26433440.
      View in: PubMed
    12. Beuers U, Gershwin ME, Gish RG, Invernizzi P, Jones DE, Lindor K, Ma X, Mackay IR, Parés A, Tanaka A, Vierling JM, Poupon R. Changing Nomenclature for PBC: From 'Cirrhosis' to 'Cholangitis'. Am J Gastroenterol. 2015 Nov; 110(11):1536-8. PMID: 26416194.
      View in: PubMed
    13. Beuers U, Gershwin ME, Gish RG, Invernizzi P, Jones DE, Lindor K, Ma X, Mackay IR, Parés A, Tanaka A, Vierling JM, Poupon R. Changing nomenclature for PBC: From 'cirrhosis' to 'cholangitis'. Dig Liver Dis. 2015 Nov; 47(11):924-6. PMID: 26419788.
      View in: PubMed
    14. Beuers U, Gershwin ME, Gish RG, Invernizzi P, Jones DE, Lindor K, Ma X, Mackay IR, Parés A, Tanaka A, Vierling JM, Poupon R. Changing Nomenclature for PBC: From 'Cirrhosis' to 'Cholangitis'. Clin Gastroenterol Hepatol. 2015 Nov; 13(11):1867-9. PMID: 26386643.
      View in: PubMed
    15. Beuers U, Gershwin ME, Gish RG, Invernizzi P, Jones DE, Lindor K, Ma X, Mackay IR, Parés A, Tanaka A, Vierling JM, Poupon R. Changing nomenclature for PBC: From 'cirrhosis' to 'cholangitis'. Hepatology. 2015 Nov; 62(5):1620-2. PMID: 26372460.
      View in: PubMed
    16. Beuers U, Gershwin ME, Gish RG, Invernizzi P, Jones DE, Lindor K, Ma X, Mackay IR, Parés A, Tanaka A, Vierling JM, Poupon R. Changing nomenclature for PBC: from 'cirrhosis' to 'cholangitis'. Gastroenterology. 2015 Nov; 149(6):1627-9. PMID: 26385706.
      View in: PubMed
    17. Beuers U, Gershwin ME, Gish RG, Invernizzi P, Jones DE, Lindor K, Ma X, Mackay IR, Parés A, Tanaka A, Vierling JM, Poupon R. Changing nomenclature for PBC: From 'cirrhosis' to 'cholangitis'. J Hepatol. 2015 Nov; 63(5):1285-7. PMID: 26385765.
      View in: PubMed
    18. Beuers U, Gershwin ME, Gish RG, Invernizzi P, Jones DE, Lindor K, Ma X, Mackay IR, Parés A, Tanaka A, Vierling JM, Poupon R. Changing nomenclature for PBC: from 'cirrhosis' to 'cholangitis'. Gut. 2015 Nov; 64(11):1671-2. PMID: 26374822.
      View in: PubMed
    19. Lagging M, Brown A, Mantry PS, Ramji A, Weilert F, Vierling JM, Howe A, Gendrano IN, Hwang P, Zhang B, Wahl J, Robertson M, Mobashery N. Grazoprevir plus peginterferon and ribavirin in treatment-naive patients with hepatitis C virus genotype 1 infection: a randomized trial. J Viral Hepat. 2016 Feb; 23(2):80-8. PMID: 26353843.
      View in: PubMed
    20. Vierling JM. Autoimmune Hepatitis and Overlap Syndromes: Diagnosis and Management. Clin Gastroenterol Hepatol. 2015 Nov; 13(12):2088-108. PMID: 26284592.
      View in: PubMed
    21. Zeuzem S, Flisiak R, Vierling JM, Mazur W, Mazzella G, Thongsawat S, Abdurakhmanov D, Van Kính N, Calistru P, Heo J, Stanciu C, Gould M, Makara M, Hsu SJ, Buggisch P, Samuel D, Mutimer D, Nault B, Merz M, Bao W, Griffel LH, Brass C, Naoumov NV. Randomised clinical trial: alisporivir combined with peginterferon and ribavirin in treatment-naïve patients with chronic HCV genotype 1 infection (ESSENTIAL II). Aliment Pharmacol Ther. 2015 Oct; 42(7):829-44. PMID: 26238707.
      View in: PubMed
    22. Vierling JM. Legal Responsibilities of Physicians When They Diagnose Hepatic Encephalopathy. Clin Liver Dis. 2015 Aug; 19(3):577-89. PMID: 26195210.
      View in: PubMed
    23. Muir AJ, Poordad F, Lalezari J, Everson G, Dore GJ, Herring R, Sheikh A, Kwo P, Hézode C, Pockros PJ, Tran A, Yozviak J, Reau N, Ramji A, Stuart K, Thompson AJ, Vierling J, Freilich B, Cooper J, Ghesquiere W, Yang R, McPhee F, Hughes EA, Swenson ES, Yin PD. Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C virus genotype 1 infection with compensated cirrhosis. JAMA. 2015 May 5; 313(17):1736-44. PMID: 25942724.
      View in: PubMed
    24. Sahebjam F, Vierling JM. Autoimmune hepatitis. Front Med. 2015 Jun; 9(2):187-219. PMID: 25749982.
      View in: PubMed
    25. Jensen D, Sherman KE, Hézode C, Pol S, Zeuzem S, de Ledinghen V, Tran A, Elkhashab M, Younes ZH, Kugelmas M, Mauss S, Everson G, Luketic V, Vierling J, Serfaty L, Brunetto M, Heo J, Bernstein D, McPhee F, Hennicken D, Mendez P, Hughes E, Noviello S. Daclatasvir and asunaprevir plus peginterferon alfa and ribavirin in HCV genotype 1 or 4 non-responders. J Hepatol. 2015 Jul; 63(1):30-7. PMID: 25703086.
      View in: PubMed
    26. Sulkowski M, Hezode C, Gerstoft J, Vierling JM, Mallolas J, Pol S, Kugelmas M, Murillo A, Weis N, Nahass R, Shibolet O, Serfaty L, Bourliere M, DeJesus E, Zuckerman E, Dutko F, Shaughnessy M, Hwang P, Howe AY, Wahl J, Robertson M, Barr E, Haber B. Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial. Lancet. 2015 Mar 21; 385(9973):1087-97. PMID: 25467560.
      View in: PubMed
    27. Feld JJ, Jacobson IM, Jensen DM, Foster GR, Pol S, Tam E, Jablkowski M, Berak H, Vierling JM, Yoshida EM, Perez-Gomez HR, Scalori A, Hooper GJ, Tavel JA, Navarro MT, Shahdad S, Kulkarni R, Le Pogam S, Nájera I, Eng S, Lim CY, Shulman NS, Yetzer ES. Randomized study of danoprevir/ritonavir-based therapy for HCV genotype 1 patients with prior partial or null responses to peginterferon/ribavirin. J Hepatol. 2015 Feb; 62(2):294-302. PMID: 25239078.
      View in: PubMed
    28. Hézode C, Hirschfield GM, Ghesquiere W, Sievert W, Rodriguez-Torres M, Shafran SD, Thuluvath PJ, Tatum HA, Waked I, Esmat G, Lawitz EJ, Rustgi VK, Pol S, Weis N, Pockros PJ, Bourlière M, Serfaty L, Vierling JM, Fried MW, Weiland O, Brunetto MR, Everson GT, Zeuzem S, Kwo PY, Sulkowski M, Bräu N, Hernandez D, McPhee F, Wind-Rotolo M, Liu Z, Noviello S, Hughes EA, Yin PD, Schnittman S. Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study. Gut. 2015 Jun; 64(6):948-56. PMID: 25080450.
      View in: PubMed
    29. Muir AJ, Arora S, Everson G, Flisiak R, George J, Ghalib R, Gordon SC, Gray T, Greenbloom S, Hassanein T, Hillson J, Horga MA, Jacobson IM, Jeffers L, Kowdley KV, Lawitz E, Lueth S, Rodriguez-Torres M, Rustgi V, Shemanski L, Shiffman ML, Srinivasan S, Vargas HE, Vierling JM, Xu D, Lopez-Talavera JC, Zeuzem S. A randomized phase 2b study of peginterferon lambda-1a for the treatment of chronic HCV infection. J Hepatol. 2014 Dec; 61(6):1238-46. PMID: 25064437.
      View in: PubMed
    30. Khaderi S, Khan R, Safdar Z, Stribling R, Vierling JM, Goss JA, Sussman NL. Long-term follow-up of portopulmonary hypertension patients after liver transplantation. Liver Transpl. 2014 Jun; 20(6):724-7. PMID: 24648168.
      View in: PubMed
    31. Kaseb AO, Xiao L, Hassan MM, Chae YK, Lee JS, Vauthey JN, Krishnan S, Cheung S, Hassabo HM, Aloia T, Conrad C, Curley SA, Vierling JM, Jalal P, Raghav K, Wallace M, Rashid A, Abbruzzese JL, Wolff RA, Morris JS. Development and validation of insulin-like growth factor-1 score to assess hepatic reserve in hepatocellular carcinoma. J Natl Cancer Inst. 2014 May; 106(5). PMID: 24815863; PMCID: PMC4085880.
    32. Vierling JM, Zeuzem S, Poordad F, Bronowicki JP, Manns MP, Bacon BR, Esteban R, Flamm SL, Kwo PY, Pedicone LD, Deng W, Dutko FJ, DiNubile MJ, Koury KJ, Helmond FA, Wahl J, Bruno S. Safety and efficacy of boceprevir/peginterferon/ribavirin for HCV G1 compensated cirrhotics: meta-analysis of 5 trials. J Hepatol. 2014 Aug; 61(2):200-9. PMID: 24747798.
      View in: PubMed
    33. Manns MP, Vierling JM, Bacon BR, Bruno S, Shibolet O, Baruch Y, Marcellin P, Caro L, Howe AY, Fandozzi C, Gress J, Gilbert CL, Shaw PM, Cooreman MP, Robertson MN, Hwang P, Dutko FJ, Wahl J, Mobashery N. The combination of MK-5172, peginterferon, and ribavirin is effective in treatment-naive patients with hepatitis C virus genotype 1 infection without cirrhosis. Gastroenterology. 2014 Aug; 147(2):366-76.e6. PMID: 24727022.
      View in: PubMed
    34. Rockey DC, Vierling JM, Mantry P, Ghabril M, Brown RS, Alexeeva O, Zupanets IA, Grinevich V, Baranovsky A, Dudar L, Fadieienko G, Kharchenko N, Klaryts'ka I, Morozov V, Grewal P, McCashland T, Reddy KG, Reddy KR, Syplyviy V, Bass NM, Dickinson K, Norris C, Coakley D, Mokhtarani M, Scharschmidt BF. Randomized, double-blind, controlled study of glycerol phenylbutyrate in hepatic encephalopathy. Hepatology. 2014 Mar; 59(3):1073-83. PMID: 23847109; PMCID: PMC4237123.
    35. Ilyas JA, Vierling JM. An overview of emerging therapies for the treatment of chronic hepatitis C. Med Clin North Am. 2014 Jan; 98(1):17-38. PMID: 24266912.
      View in: PubMed
    36. Vierling JM, Davis M, Flamm S, Gordon SC, Lawitz E, Yoshida EM, Galati J, Luketic V, McCone J, Jacobson I, Marcellin P, Muir AJ, Poordad F, Pedicone LD, Albrecht J, Brass C, Howe AY, Colvard LY, Helmond FA, Deng W, Treitel M, Wahl J, Bronowicki JP. Boceprevir for chronic HCV genotype 1 infection in patients with prior treatment failure to peginterferon/ribavirin, including prior null response. J Hepatol. 2014 Apr; 60(4):748-56. PMID: 24362076.
      View in: PubMed
    37. Raza A, Vierling J, Hussain KB. Genetics of drug-induced hepatotoxicity toxicity in Gilbert's syndrome. Am J Gastroenterol. 2013 Dec; 108(12):1936-7. PMID: 24300875.
      View in: PubMed
    38. Hwang JP, Fisch MJ, Lok AS, Zhang H, Vierling JM, Suarez-Almazor ME. Trends in hepatitis B virus screening at the onset of chemotherapy in a large US cancer center. BMC Cancer. 2013; 13:534. PMID: 24209764; PMCID: PMC3827843.
    39. Manns MP, McCone J, Davis MN, Rossaro L, Schiff E, Shiffman ML, Bacon B, Bourliere M, Sulkowski MS, Bruno S, Balart L, Bronowicki JP, Kwo P, Poordad F, Felizarta F, Reddy KR, Helmond FA, Sings HL, Pedicone LD, Burroughs M, Brass CA, Albrecht JK, Vierling JM. Overall safety profile of boceprevir plus peginterferon alfa-2b and ribavirin in patients with chronic hepatitis C genotype 1: a combined analysis of 3 phase 2/3 clinical trials. Liver Int. 2014 May; 34(5):707-19. PMID: 24118703.
      View in: PubMed
    40. Mokhtarani M, Diaz GA, Rhead W, Berry SA, Lichter-Konecki U, Feigenbaum A, Schulze A, Longo N, Bartley J, Berquist W, Gallagher R, Smith W, McCandless SE, Harding C, Rockey DC, Vierling JM, Mantry P, Ghabril M, Brown RS, Dickinson K, Moors T, Norris C, Coakley D, Milikien DA, Nagamani SC, Lemons C, Lee B, Scharschmidt BF. Elevated phenylacetic acid levels do not correlate with adverse events in patients with urea cycle disorders or hepatic encephalopathy and can be predicted based on the plasma PAA to PAGN ratio. Mol Genet Metab. 2013 Dec; 110(4):446-53. PMID: 24144944; PMCID: PMC4108288.
    41. Pinto-Patarroyo GP, Rytting ME, Vierling JM, Suarez-Almazor ME. Haemophagocytic lymphohistiocytosis presenting as liver failure following Epstein-Barr and prior hepatitis A infections. BMJ Case Rep. 2013; 2013. PMID: 23943807; PMCID: PMC3761427.
    42. Wedemeyer H, Jensen D, Herring R, Ferenci P, Ma MM, Zeuzem S, Rodriguez-Torres M, Bzowej N, Pockros P, Vierling J, Ipe D, Munson ML, Chen YC, Najera I, Thommes J. PROPEL: a randomized trial of mericitabine plus peginterferon alpha-2a/ribavirin therapy in treatment-naïve HCV genotype 1/4 patients. Hepatology. 2013 Aug; 58(2):524-37. PMID: 23348636.
      View in: PubMed
    43. Pockros PJ, Jensen D, Tsai N, Taylor R, Ramji A, Cooper C, Dickson R, Tice A, Kulkarni R, Vierling JM, Lou Munson M, Chen YC, Najera I, Thommes J. JUMP-C: a randomized trial of mericitabine plus pegylated interferon alpha-2a/ribavirin for 24 weeks in treatment-naïve HCV genotype 1/4 patients. Hepatology. 2013 Aug; 58(2):514-23. PMID: 23359491.
      View in: PubMed
    44. Hwang JP, Vierling JM, Zelenetz AD, Lackey SC, Loomba R. Erratum to: Hepatitis B virus management to prevent reactivation after chemotherapy: a review. Support Care Cancer. 2013 Apr; 21(4):1211. PMID: 23354554.
      View in: PubMed
    45. Cobb B, Pockros PJ, Vilchez RA, Vierling JM. HCV RNA viral load assessments in the era of direct-acting antivirals. Am J Gastroenterol. 2013 Apr; 108(4):471-5. PMID: 23552304.
      View in: PubMed
    46. Ghabril M, Zupanets IA, Vierling J, Mantry P, Rockey D, Wolf D, O'Shea R, Dickinson K, Gillaspy H, Norris C, Coakley DF, Mokhtarani M, Scharschmidt BF. Glycerol Phenylbutyrate in Patients With Cirrhosis and Episodic Hepatic Encephalopathy: A Pilot Study of Safety and Effect on Venous Ammonia Concentration. Clin Pharmacol Drug Dev. 2013 Jul; 2(3):278-84. PMID: 27121790.
      View in: PubMed
    47. Kowdley KV, Lawitz E, Crespo I, Hassanein T, Davis MN, DeMicco M, Bernstein DE, Afdhal N, Vierling JM, Gordon SC, Anderson JK, Hyland RH, Dvory-Sobol H, An D, Hindes RG, Albanis E, Symonds WT, Berrey MM, Nelson DR, Jacobson IM. Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial. Lancet. 2013 Jun 15; 381(9883):2100-7. PMID: 23499440.
      View in: PubMed
    48. Ogert RA, Howe JA, Vierling JM, Kwo PY, Lawitz EJ, McCone J, Schiff ER, Pound D, Davis MN, Gordon SC, Ravendhran N, Rossaro L, Jacobson IM, Ralston R, Chaudhri E, Qiu P, Pedicone LD, Brass CA, Albrecht JK, Barnard RJ, Hazuda DJ, Howe AY. Resistance-associated amino acid variants associated with boceprevir plus pegylated interferon-?2b and ribavirin in patients with chronic hepatitis C in the SPRINT-1 trial. Antivir Ther. 2013; 18(3):387-97. PMID: 23406826.
      View in: PubMed
    49. Vierling JM. Hepatitis C virus viral assays in the direct-acting antiviral era. Clin Liver Dis. 2013 Feb; 17(1):27-45. PMID: 23177281.
      View in: PubMed
    50. Selmi C, Ceribelli A, Vierling JM. Suspected and unsuspected factors in the multifaceted immunopathology of viral hepatitis. Semin Immunopathol. 2013 Jan; 35(1):1-5. PMID: 23250654.
      View in: PubMed
    51. Bruno S, Vierling JM, Esteban R, Nyberg LM, Tanno H, Goodman Z, Poordad F, Bacon B, Gottesdiener K, Pedicone LD, Albrecht JK, Brass CA, Thompson S, Burroughs MH. Efficacy and safety of boceprevir plus peginterferon-ribavirin in patients with HCV G1 infection and advanced fibrosis/cirrhosis. J Hepatol. 2013 Mar; 58(3):479-87. PMID: 23183529.
      View in: PubMed
    52. Flamm SL, Lawitz E, Jacobson I, Bourlière M, Hezode C, Vierling JM, Bacon BR, Niederau C, Sherman M, Goteti V, Sings HL, Barnard RO, Howe JA, Pedicone LD, Burroughs MH, Brass CA, Albrecht JK, Poordad F. Boceprevir with peginterferon alfa-2a-ribavirin is effective for previously treated chronic hepatitis C genotype 1 infection. Clin Gastroenterol Hepatol. 2013 Jan; 11(1):81-87.e4; quiz e5. PMID: 23064222.
      View in: PubMed
    53. Hwang JP, Vierling JM, Zelenetz AD, Lackey SC, Loomba R. Hepatitis B virus management to prevent reactivation after chemotherapy: a review. Support Care Cancer. 2012 Nov; 20(11):2999-3008. PMID: 22933131; PMCID: PMC3469760.
    54. Hwang JP, Fisch MJ, Zhang H, Kallen MA, Routbort MJ, Lal LS, Vierling JM, Suarez-Almazor ME. Low rates of hepatitis B virus screening at the onset of chemotherapy. J Oncol Pract. 2012 Jul; 8(4):e32-9. PMID: 23180996; PMCID: PMC3396827.
    55. Harrison SA, Hamzeh FM, Han J, Pandya PK, Sheikh MY, Vierling JM. Chronic hepatitis C genotype 1 patients with insulin resistance treated with pioglitazone and peginterferon alpha-2a plus ribavirin. Hepatology. 2012 Aug; 56(2):464-73. PMID: 22334369.
      View in: PubMed
    56. Tsuda M, Moritoki Y, Lian ZX, Zhang W, Yoshida K, Wakabayashi K, Yang GX, Nakatani T, Vierling J, Lindor K, Gershwin ME, Bowlus CL. Biochemical and immunologic effects of rituximab in patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid. Hepatology. 2012 Feb; 55(2):512-21. PMID: 22006563.
      View in: PubMed
    57. Vierling JM. Diagnosis and treatment of autoimmune hepatitis. Curr Gastroenterol Rep. 2012 Feb; 14(1):25-36. PMID: 22179843.
      View in: PubMed
    58. Ilyas JA, O'Mahony CA, Vierling JM. Liver transplantation in autoimmune liver diseases. Best Pract Res Clin Gastroenterol. 2011 Dec; 25(6):765-82. PMID: 22117641.
      View in: PubMed
    59. Ilyas JA, Vierling JM. An overview of emerging therapies for the treatment of chronic hepatitis C. Clin Liver Dis. 2011 Aug; 15(3):515-36. PMID: 21867934.
      View in: PubMed
    60. Nguyen NT, Vierling JM. Acute liver failure. Curr Opin Organ Transplant. 2011 Jun; 16(3):289-96. PMID: 21519261.
      View in: PubMed
    61. Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, Poordad F, Goodman ZD, Sings HL, Boparai N, Burroughs M, Brass CA, Albrecht JK, Esteban R. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med. 2011 Mar 31; 364(13):1207-17. PMID: 21449784; PMCID: PMC3153125.
    62. Merwat SN, Vierling JM. HIV infection and the liver: the importance of HCV-HIV coinfection and drug-induced liver injury. Clin Liver Dis. 2011 Feb; 15(1):131-52. PMID: 21111997.
      View in: PubMed
    63. Vierling JM. Autoimmune hepatitis and antigen-specific T regulatory cells: when can we send in the regulators? Hepatology. 2011 Feb; 53(2):385-8. PMID: 21274860.
      View in: PubMed
    64. Vierling JM, Hreha G, Wang H, Braun M. The role of biliary epithelial cells in the immunopathogenesis of non-suppurative destructive cholangitis in murine hepatic graft-versus-host disease. Trans Am Clin Climatol Assoc. 2011; 122:326-35. PMID: 21686235; PMCID: PMC3116360.
    65. Muir AJ, Shiffman ML, Zaman A, Yoffe B, de la Torre A, Flamm S, Gordon SC, Marotta P, Vierling JM, Lopez-Talavera JC, Byrnes-Blake K, Fontana D, Freeman J, Gray T, Hausman D, Hunder NN, Lawitz E. Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection. Hepatology. 2010 Sep; 52(3):822-32. PMID: 20564352.
      View in: PubMed
    66. Kwo PY, Lawitz EJ, McCone J, Schiff ER, Vierling JM, Pound D, Davis MN, Galati JS, Gordon SC, Ravendhran N, Rossaro L, Anderson FH, Jacobson IM, Rubin R, Koury K, Pedicone LD, Brass CA, Chaudhri E, Albrecht JK. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet. 2010 Aug 28; 376(9742):705-16. PMID: 20692693.
      View in: PubMed
    67. Manns MP, Czaja AJ, Gorham JD, Krawitt EL, Mieli-Vergani G, Vergani D, Vierling JM. Diagnosis and management of autoimmune hepatitis. Hepatology. 2010 Jun; 51(6):2193-213. PMID: 20513004.
      View in: PubMed
    68. Hwang JP, Mohseni M, Gor BJ, Wen S, Guerrero H, Vierling JM. Hepatitis B and hepatitis C prevalence and treatment referral among Asian Americans undergoing community-based hepatitis screening. Am J Public Health. 2010 Apr 1; 100 Suppl 1:S118-24. PMID: 20147697; PMCID: PMC2837431.
    69. He Y, Wu GD, Sadahiro T, Noh SI, Wang H, Talavera D, Wang H, Vierling JM, Klein AS. Interaction of CD44 and hyaluronic acid enhances biliary epithelial proliferation in cholestatic livers. Am J Physiol Gastrointest Liver Physiol. 2008 Aug; 295(2):G305-12. PMID: 18556418.
      View in: PubMed
    70. Selmi C, Gershwin ME, Lindor KD, Worman HJ, Gold EB, Watnik M, Utts J, Invernizzi P, Kaplan MM, Vierling JM, Bowlus CL, Silveira MG, Bossi I. Quality of life and everyday activities in patients with primary biliary cirrhosis. Hepatology. 2007 Dec; 46(6):1836-43. PMID: 18027862; PMCID: PMC3148769.
    71. Vierling JM. The immunology of hepatitis B. Clin Liver Dis. 2007 Nov; 11(4):727-59, vii-viii. PMID: 17981227.
      View in: PubMed
    72. Choi WC, Arnaout WC, Villamil FG, Demetriou AA, Vierling JM. Comparison of the applicability of two prognostic scoring systems in patients with fulminant hepatic failure. Korean J Intern Med. 2007 Jun; 22(2):93-100. PMID: 17616024; PMCID: PMC2687618.
    73. Barshes NR, Horwitz IB, Franzini L, Vierling JM, Goss JA. Waitlist mortality decreases with increased use of extended criteria donor liver grafts at adult liver transplant centers. Am J Transplant. 2007 May; 7(5):1265-70. PMID: 17359503.
      View in: PubMed
    74. Barshes NR, Hacker CS, Freeman RB, Vierling JM, Goss JA. Justice, administrative law, and the transplant clinician: the ethical and legislative basis of a national policy on donor liver allocation. J Contemp Health Law Policy. 2007; 23(2):200-30. PMID: 17642381.
      View in: PubMed
    75. Freeman RB, Gish RG, Harper A, Davis GL, Vierling J, Lieblein L, Klintmalm G, Blazek J, Hunter R, Punch J. Model for end-stage liver disease (MELD) exception guidelines: results and recommendations from the MELD Exception Study Group and Conference (MESSAGE) for the approval of patients who need liver transplantation with diseases not considered by the standard MELD formula. Liver Transpl. 2006 Dec; 12(12 Suppl 3):S128-36. PMID: 17123284.
      View in: PubMed
    76. Sussman N, Kaza V, Barshes N, Stribling R, Goss J, O'Mahony C, Zhang E, Vierling J, Frost A. Successful liver transplantation following medical management of portopulmonary hypertension: a single-center series. Am J Transplant. 2006 Sep; 6(9):2177-82. PMID: 16796721.
      View in: PubMed
    77. Stribling R, Sussman N, Vierling JM. Treatment of hepatitis C infection. Gastroenterol Clin North Am. 2006 Jun; 35(2):463-86. PMID: 16880075.
      View in: PubMed
    78. Tran TT, Changsri C, Shackleton CR, Poordad FF, Nissen NN, Colquhoun S, Geller SA, Vierling JM, Martin P. Living donor liver transplantation: histological abnormalities found on liver biopsies of apparently healthy potential donors. J Gastroenterol Hepatol. 2006 Feb; 21(2):381-3. PMID: 16509862.
      View in: PubMed
    79. O'Mahony CA, Vierling JM. Etiopathogenesis of primary sclerosing cholangitis. Semin Liver Dis. 2006 Feb; 26(1):3-21. PMID: 16496229.
      View in: PubMed
    80. Saab S, Nguyen S, Ibrahim A, Vierling JM, Tong MJ. Management of patients with cirrhosis in Southern California: results of a practitioner survey. J Clin Gastroenterol. 2006 Feb; 40(2):156-61. PMID: 16394878.
      View in: PubMed
    81. Gershwin ME, Selmi C, Worman HJ, Gold EB, Watnik M, Utts J, Lindor KD, Kaplan MM, Vierling JM. Risk factors and comorbidities in primary biliary cirrhosis: a controlled interview-based study of 1032 patients. Hepatology. 2005 Nov; 42(5):1194-202. PMID: 16250040; PMCID: PMC3150736.
    82. Shackleton CR, Vierling JM, Nissen N, Martin P, Poordad F, Tran T, Colquhoun SD. Morbidity in live liver donors: standards-based adverse event reporting further refined. Arch Surg. 2005 Sep; 140(9):888-95; discussion 895-6. PMID: 16172298.
      View in: PubMed
    83. Vierling JM. Future Treatment Options in PBC. Semin Liver Dis. 2005 Aug; 25(3):347-63. PMID: 16143950.
      View in: PubMed
    84. Ichiki Y, Bowlus CL, Shimoda S, Ishibashi H, Vierling JM, Gershwin ME. T cell immunity and graft-versus-host disease (GVHD). Autoimmun Rev. 2006 Jan; 5(1):1-9. PMID: 16338205.
      View in: PubMed
    85. Vierling JM. Management of HBV Infection in Liver Transplantation Patients. Int J Med Sci. 2005; 2(1):41-49. PMID: 15968339.
      View in: PubMed
    86. Ayoub WS, Geller SA, Tran T, Martin P, Vierling JM, Poordad FF. Imatinib (Gleevec)-induced hepatotoxicity. J Clin Gastroenterol. 2005 Jan; 39(1):75-7. PMID: 15599217.
      View in: PubMed
    87. Czaja AJ, Bianchi FB, Carpenter HA, Krawitt EL, Lohse AW, Manns MP, McFarlane IG, Mieli-Vergani G, Toda G, Vergani D, Vierling J, Zeniya M. Treatment challenges and investigational opportunities in autoimmune hepatitis. Hepatology. 2005 Jan; 41(1):207-15. PMID: 15690485.
      View in: PubMed
    88. Geller SA, Dubinsky MC, Poordad FF, Vasiliauskas EA, Cohen AH, Abreu MT, Tran T, Martin P, Vierling JM, Targan SR. Early hepatic nodular hyperplasia and submicroscopic fibrosis associated with 6-thioguanine therapy in inflammatory bowel disease. Am J Surg Pathol. 2004 Sep; 28(9):1204-11. PMID: 15316320.
      View in: PubMed
    89. Papadakis KA, Matuk R, Abreu MT, Vasiliauskas EA, Fleshner PR, Lechago J, Tran T, Poordad FF, Martin P, Vierling J, Targan SR. Crohn's ileitis after liver transplantation from a living related donor with Crohn's disease. Gut. 2004 Sep; 53(9):1389-90. PMID: 15306609; PMCID: PMC1774186.
    90. Xu J, Lee G, Wang H, Vierling JM, Maher JJ. Limited role for CXC chemokines in the pathogenesis of alpha-naphthylisothiocyanate-induced liver injury. Am J Physiol Gastrointest Liver Physiol. 2004 Sep; 287(3):G734-41. PMID: 15130876; PMCID: PMC3622103.
    91. Firpi RJ, Tran TT, Flores P, Nissen N, Colquhoun S, Shackleton C, Martin P, Vierling JM, Poordad FF. Sirolimus-induced hyperlipidaemia in liver transplant recipients is not dose-dependent. Aliment Pharmacol Ther. 2004 May 1; 19(9):1033-9. PMID: 15113371.
      View in: PubMed
    92. Vierling JM. Primary biliary cirrhosis and autoimmune cholangiopathy. Clin Liver Dis. 2004 Feb; 8(1):177-94. PMID: 15062200.
      View in: PubMed
    93. Braun M, Vierling JM. The clinical and immunologic impact of using interferon and ribavirin in the immunosuppressed host. Liver Transpl. 2003 Nov; 9(11):S79-89. PMID: 14586901.
      View in: PubMed
    94. Dubinsky MC, Vasiliauskas EA, Singh H, Abreu MT, Papadakis KA, Tran T, Martin P, Vierling JM, Geller SA, Targan SR, Poordad FF. 6-thioguanine can cause serious liver injury in inflammatory bowel disease patients. Gastroenterology. 2003 Aug; 125(2):298-303. PMID: 12891528.
      View in: PubMed
    95. Bunnapradist S, Fabrizi F, Vierling J, Martin R, Moudgil A, Kamil E, Jordan S. Hepatitis C therapy with long term remission after renal transplantation. Int J Artif Organs. 2002 Dec; 25(12):1189-93. PMID: 12518964.
      View in: PubMed
    96. Collisson EA, Nourmand H, Fraiman MH, Cooper CB, Bellamy PE, Farmer DG, Vierling JM, Ghobrial RM, Busuttil RW. Retrospective analysis of the results of liver transplantation for adults with severe hepatopulmonary syndrome. Liver Transpl. 2002 Oct; 8(10):925-31. PMID: 12360435.
      View in: PubMed
    97. Fontana RJ, Hann HW, Perrillo RP, Vierling JM, Wright T, Rakela J, Anschuetz G, Davis R, Gardner SD, Brown NA. Determinants of early mortality in patients with decompensated chronic hepatitis B treated with antiviral therapy. Gastroenterology. 2002 Sep; 123(3):719-27. PMID: 12198698.
      View in: PubMed
    98. Shackleton CR, Colquhoun SD, Vierling JM. Transplantation of the right hepatic lobe. N Engl J Med. 2002 Aug 22; 347(8):615-8; author reply 615-8. PMID: 12195588.
      View in: PubMed
    99. Vierling JM, Flores PA. Evolving new therapies of autoimmune hepatitis. Clin Liver Dis. 2002 Aug; 6(3):825-50, ix. PMID: 12362583.
      View in: PubMed
    100. Amankonah TD, Strom CB, Vierling JM, Petrovic LM. Inflammatory pseudotumor of the liver as the first manifestation of Crohn's disease. Am J Gastroenterol. 2001 Aug; 96(8):2520-2. PMID: 11513216.
      View in: PubMed
    101. Vierling JM. Animal models for primary sclerosing cholangitis. Best Pract Res Clin Gastroenterol. 2001 Aug; 15(4):591-610. PMID: 11492970.
      View in: PubMed
    102. Yu AS, Vierling JM, Colquhoun SD, Arnaout WS, Chan CK, Khanafshar E, Geller SA, Nichols WS, Fong TL. Transmission of hepatitis B infection from hepatitis B core antibody--positive liver allografts is prevented by lamivudine therapy. Liver Transpl. 2001 Jun; 7(6):513-7. PMID: 11443579.
      View in: PubMed
    103. Hu KQ, Vierling JM, Redeker AG. Viral, host and interferon-related factors modulating the effect of interferon therapy for hepatitis C virus infection. J Viral Hepat. 2001 Jan; 8(1):1-18. PMID: 11155147.
      View in: PubMed
    104. Garcia G, Petrovic LM, Vierling JM. Overview of hepatitis B and transplantation in the hepatitis B patient. Semin Liver Dis. 2000; 20 Suppl 1:3-6. PMID: 10895437.
      View in: PubMed
    105. Vierling JM, Teperman LW, Lake JR, Perrillo RP, Peters M, Fried M, Schiff ER. Case studies of the hepatitis B patient: a panel discussion. Semin Liver Dis. 2000; 20 Suppl 1:29-35. PMID: 10895442.
      View in: PubMed
    106. Vierling JM, Teperman LW. Introduction to hepatitis B transplantation. Semin Liver Dis. 2000; 20 Suppl 1:1-2. PMID: 10895436.
      View in: PubMed
    107. Peters MG, Shouval D, Bonham A, Vierling JM, Lok AS. Posttransplantation: future therapies. Semin Liver Dis. 2000; 20 Suppl 1:19-24. PMID: 10895440.
      View in: PubMed
    108. Hreha G, Jefferson DM, Yu CH, Grubman SA, Alsabeh R, Geller SA, Vierling JM. Immortalized intrahepatic mouse biliary epithelial cells: immunologic characterization and immunogenicity. Hepatology. 1999 Aug; 30(2):358-71. PMID: 10421641.
      View in: PubMed
    109. Vierling JM. Autoimmune cholangiopathy. Clin Liver Dis. 1999 Aug; 3(3):571-84. PMID: 11291239.
      View in: PubMed
    110. Vierling JM. Immunology of acute and chronic hepatic allograft rejection. Liver Transpl Surg. 1999 Jul; 5(4 Suppl 1):S1-S20. PMID: 10431013.
      View in: PubMed
    111. Fernandes NF, Redeker AG, Vierling JM, Villamil FG, Fong TL. Cyclosporine therapy in patients with steroid resistant autoimmune hepatitis. Am J Gastroenterol. 1999 Jan; 94(1):241-8. PMID: 9934764.
      View in: PubMed
    112. Goldman DE, Colquhoun SD, Ghobrial RM, Arnaout WS, Farmer DG, Markmann JF, Shackleton CR, Vierling JM, Busuttil RW. Mycotic aneurysm of arterial conduit presenting as massive upper gastrointestinal hemorrhage after liver transplantation. Liver Transpl Surg. 1998 Sep; 4(5):435-6. PMID: 9724483.
      View in: PubMed
    113. Coffman KL, Sher L, Hoffman A, Rojter S, Folk P, Cramer DV, Vierling J, Villamel F, Podesta L, Demetriou A, Makowka L. Survey results of transplant patients' attitudes on xenografting. Psychosomatics. 1998 Jul-Aug; 39(4):379-83. PMID: 9691708.
      View in: PubMed
    114. Ghany MG, Ayola B, Villamil FG, Gish RG, Rojter S, Vierling JM, Lok AS. Hepatitis B virus S mutants in liver transplant recipients who were reinfected despite hepatitis B immune globulin prophylaxis. Hepatology. 1998 Jan; 27(1):213-22. PMID: 9425940.
      View in: PubMed
    115. Hamid S, Rojter S, Vierling J. Protracted cholestatic hepatitis after the use of prostata. Ann Intern Med. 1997 Jul 15; 127(2):169-70. PMID: 9230022.
      View in: PubMed
    116. Petrovic LM, Villamil FG, Vierling JM, Makowka L, Geller SA. Comparison of histopathology in acute allograft rejection and recurrent hepatitis C infection after liver transplantation. Liver Transpl Surg. 1997 Jul; 3(4):398-406. PMID: 9346770.
      View in: PubMed
    117. Coffman KL, Hoffman A, Sher L, Rojter S, Vierling J, Makowka L. Treatment of the postoperative alcoholic liver transplant recipient with other addictions. Liver Transpl Surg. 1997 May; 3(3):322-7. PMID: 9346758.
      View in: PubMed
    118. Watanabe FD, Shackleton CR, Cohen SM, Goldman DE, Arnaout WS, Hewitt W, Colquhoun SD, Fong TL, Vierling JM, Busuttil RW, Demetriou AA. Treatment of acetaminophen-induced fulminant hepatic failure with a bioartificial liver. Transplant Proc. 1997 Feb-Mar; 29(1-2):487-8. PMID: 9123096.
      View in: PubMed
    119. Trépo C, Vierling J, Zeytin FN, Gerlich WH. The first Flaviviridae symposium. Intervirology. 1997; 40(4):279-88. PMID: 9612731.
      View in: PubMed
    120. Vierling JM, Villamil FG, Rojter SE, Camacho KB, Goldman DE. Morbidity and mortality of recurrent hepatitis C infection after orthotopic liver transplantation. J Viral Hepat. 1997; 4 Suppl 1:117-24. PMID: 9097290.
      View in: PubMed
    121. Geller SA, Nichols WS, Rojter SE, Chan RC, Petrovic LM, Vierling JM, Makowka L. Hepatitis C virus is not recoverable from liver tissue in cryptogenic cirrhosis: failure to identify hepatitis C virus-RNA using reverse transcription-mediated polymerase chain reaction. Hum Pathol. 1996 Nov; 27(11):1161-5. PMID: 8912825.
      View in: PubMed
    122. Cosenza CA, Hoffman AL, Friedman ML, Sher LS, Lopez RR, Van Allen R, Brown DH, Fraiman MH, Arnaout W, Vierling J, Makowka L. Transjugular intrahepatic portosystemic shunt: efficacy for the treatment of portal hypertension and impact on liver transplantation. Am Surg. 1996 Oct; 62(10):835-9. PMID: 8813166.
      View in: PubMed
    123. Sher LS, Cosenza CA, Petrovic LM, Rojter S, Hoffman A, Lopez RR, Meehan M, Pan SH, Vierling J, Makowka L. Tacrolimus (FK 506) for rescue of chronic rejection following orthotopic liver transplantation. Transplant Proc. 1996 Apr; 28(2):1011-3. PMID: 8623212.
      View in: PubMed
    124. Villamil FG, Hu KQ, Yu CH, Lee CH, Rojter SE, Podesta LG, Makowka L, Geller SA, Vierling JM. Detection of hepatitis C virus with RNA polymerase chain reaction in fulminant hepatic failure. Hepatology. 1995 Nov; 22(5):1379-86. PMID: 7590651.
      View in: PubMed
    125. Narkewicz MR, Smith D, Silverman A, Vierling J, Sokol RJ. Clearance of chronic hepatitis B virus infection in young children after alpha interferon treatment. J Pediatr. 1995 Nov; 127(5):815-8. PMID: 7472844.
      View in: PubMed
    126. Silverman JM, Podesta L, Villamil F, Sher L, Vierling J, Rojter S, Hoffman A, Lopez R, Rosenthal P, Woolf G, et al. Portal vein patency in candidates for liver transplantation: MR angiographic analysis. Radiology. 1995 Oct; 197(1):147-52. PMID: 7568813.
      View in: PubMed
    127. Villamil FG, Vierling JM. Recurrence of viral hepatitis after liver transplantation: insights into management. Liver Transpl Surg. 1995 Sep; 1(5 Suppl 1):89-99. PMID: 9346605.
      View in: PubMed
    128. Rojter S, Villamil FG, Petrovic LM, Silverman JM, Woolf GM, Podesta LG, Makowka L, Vierling JM. Malignant vascular tumors of the liver presenting as liver failure and portal hypertension. Liver Transpl Surg. 1995 May; 1(3):156-61. PMID: 9346558.
      View in: PubMed
    129. Hu KQ, Yu CH, Lee S, Villamil FG, Vierling JM. Simultaneous detection of both hepatitis B virus DNA and hepatitis C virus RNA using a combined one-step polymerase chain reaction technique. Hepatology. 1995 Apr; 21(4):901-7. PMID: 7705799.
      View in: PubMed
    130. Woolf GM, Petrovic LM, Rojter SE, Wainwright S, Villamil FG, Katkov WN, Michieletti P, Wanless IR, Stermitz FR, Beck JJ, Vierling JM. Acute hepatitis associated with the Chinese herbal product jin bu huan. Ann Intern Med. 1994 Nov 15; 121(10):729-35. PMID: 7944049.
      View in: PubMed
    131. Hu KQ, Vierling JM. Molecular diagnostic techniques for viral hepatitis. Gastroenterol Clin North Am. 1994 Sep; 23(3):479-98. PMID: 7989090.
      View in: PubMed
    132. Woolf GM, Petrovic LM, Rojter SE, Villamil FG, Makowka L, Podesta LG, Sher LS, Memsic L, Vierling JM. Acute liver failure due to lymphoma. A diagnostic concern when considering liver transplantation. Dig Dis Sci. 1994 Jun; 39(6):1351-8. PMID: 8200270.
      View in: PubMed
    133. Hu KQ, Yu CH, Vierling JM. One-step RNA polymerase chain reaction for detection of hepatitis C virus RNA. Hepatology. 1993 Aug; 18(2):270-4. PMID: 7687979.
      View in: PubMed
    134. Woolf GM, Vierling JM. Disappearing intrahepatic bile ducts: the syndromes and their mechanisms. Semin Liver Dis. 1993 Aug; 13(3):261-75. PMID: 8235716.
      View in: PubMed
    135. Hu KQ, Yu CH, Vierling JM. Up-regulation of intercellular adhesion molecule 1 transcription by hepatitis B virus X protein. Proc Natl Acad Sci U S A. 1992 Dec 1; 89(23):11441-5. PMID: 1360668; PMCID: PMC50567.
    136. Vierling JM. Immune disorders of the liver and bile duct. Gastroenterol Clin North Am. 1992 Jun; 21(2):427-49. PMID: 1512050.
      View in: PubMed
    137. Hu KQ, Yu CH, Vierling JM. Direct detection of circulating hepatitis C virus RNA using probes from the 5' untranslated region. J Clin Invest. 1992 Jun; 89(6):2040-5. PMID: 1318328; PMCID: PMC295919.
    138. Howell CD, Yoder TY, Vierling JM. Suppressor function of liver mononuclear cells isolated during murine chronic graft-vs-host disease. II. Role of prostaglandins and interferon-gamma. Cell Immunol. 1992 Mar; 140(1):54-66. PMID: 1531454.
      View in: PubMed
    139. Vierling JM. Immunologic mechanisms of hepatic allograft rejection. Semin Liver Dis. 1992 Feb; 12(1):16-27. PMID: 1570548.
      View in: PubMed
    140. Peters M, Vierling J, Gershwin ME, Milich D, Chisari FV, Hoofnagle JH. Immunology and the liver. Hepatology. 1991 May; 13(5):977-94. PMID: 2030002.
      View in: PubMed
    141. Howell CD, Yoder TD, Vierling JM. Suppressor function of hepatic mononuclear inflammatory cells during murine chronic graft-vs-host disease. I. Macrophage-enriched cells mediate suppression in the liver. Cell Immunol. 1991 Jan; 132(1):256-68. PMID: 1829654.
      View in: PubMed
    142. Hu KQ, Vierling JM, Siddiqui A. Trans-activation of HLA-DR gene by hepatitis B virus X gene product. Proc Natl Acad Sci U S A. 1990 Sep; 87(18):7140-4. PMID: 2169620; PMCID: PMC54699.
    143. Vierling JM, Howell CD. Disappearing bile ducts: immunologic mechanisms. Hosp Pract (Off Ed). 1990 Jul 15; 25(7):141-50. PMID: 2115531.
      View in: PubMed
    144. Gholson CF, Siddiqui A, Vierling JM. Cell surface expression of hepatitis B surface and core antigens in transfected rat fibroblast cell lines. Gastroenterology. 1990 Apr; 98(4):968-75. PMID: 2179036.
      View in: PubMed
    145. Vierling JM, Ruderman WB, Jaffee BD, Fennell RH, Claman HN. Hepatic lesions in murine chronic graft-versus-host disease to minor histocompatibility antigens. A reproducible model of nonsuppurative destructive cholangitis. Transplantation. 1989 Oct; 48(4):717-8. PMID: 2799935.
      View in: PubMed
    146. Howell CD, Yoder T, Claman HN, Vierling JM. Hepatic homing of mononuclear inflammatory cells isolated during murine chronic graft-vs-host disease. J Immunol. 1989 Jul 15; 143(2):476-83. PMID: 2472440.
      View in: PubMed
    147. Vierling JM. Biliary victories: studies of isolated biliary epithelial cells. J Lab Clin Med. 1989 Jun; 113(6):663-4. PMID: 2732615.
      View in: PubMed
    148. Mizuno M, Yamada G, Sugiyama T, Vierling JM, Brown WR. Monoclonal antibodies identifying antigens on distinct domains of rat hepatocytes. Liver. 1987 Oct; 7(5):251-9. PMID: 3695813.
      View in: PubMed
    149. Perino LE, Vierling JM. Chyloperitoneum with collateral lymphatic drainage involving abdominal skin. Dig Dis Sci. 1987 Jun; 32(6):660-4. PMID: 3568953.
      View in: PubMed
    150. Berry WR, Gottesfeld RL, Alter HJ, Vierling JM. Transmission of hepatitis B virus by artificial insemination. JAMA. 1987 Feb 27; 257(8):1079-81. PMID: 3806899.
      View in: PubMed
    151. Styne PN, Vierling JM. Isolated perfusion of murine liver in situ: technique and validation. Am J Physiol. 1985 Dec; 249(6 Pt 1):G719-24. PMID: 4083353.
      View in: PubMed
    152. Vierling JM, Fennell RH. Histopathology of early and late human hepatic allograft rejection: evidence of progressive destruction of interlobular bile ducts. Hepatology. 1985 Nov-Dec; 5(6):1076-82. PMID: 3905558.
      View in: PubMed
    153. Fennell RH, Vierling JM. Electron microscopy of rejected human liver allografts. Hepatology. 1985 Nov-Dec; 5(6):1083-7. PMID: 3905559.
      View in: PubMed
    154. Finck MH, Reichen J, Vierling JM, Kloppel TM, Brown WR. Hepatic uptake and disposition of human polymeric IgA1 in perfused rat liver: evidence for incomplete biliary excretion and intrahepatic degradation. Am J Physiol. 1985 Apr; 248(4 Pt 1):G450-5. PMID: 3985150.
      View in: PubMed
    155. Mizuno M, Brown WR, Vierling JM. Ultrastructural immunocytochemical localization of the asialoglycoprotein receptor in rat hepatocytes. Gastroenterology. 1984 Oct; 87(4):763-9. PMID: 6088350.
      View in: PubMed
    156. Mizuno M, Kloppel TM, Nakane PK, Brown WR, Vierling JM. Cellular distribution of the asialoglycoprotein receptor in rat liver. Implications for hepatic accumulation of desialylated lymphocytes. Gastroenterology. 1984 Jan; 86(1):142-9. PMID: 6315523.
      View in: PubMed
    157. Vierling JM. Epidemiology and clinical course of liver diseases: identification of candidates for hepatic transplantation. Hepatology. 1984 Jan-Feb; 4(1 Suppl):84S-94S. PMID: 6363265.
      View in: PubMed
    158. Vierling JM. Hepatic injury by prescription medication. Med Sect Proc. 1983; 79-86. PMID: 6678434.
      View in: PubMed
    159. Fennell RH, Shikes RH, Vierling JM. Relationship of pretransplant hepatobiliary disease to bile duct damage occurring in the liver allograft. Hepatology. 1983 Jan-Feb; 3(1):84-9. PMID: 6295909.
      View in: PubMed
    160. Vierling JM. Alcoholic liver injuries--update. Med Sect Proc. 1983; 87-93. PMID: 6678435.
      View in: PubMed
    161. Vierling JM, Berk PD, Hofmann AF, Martin JF, Wolkoff AW, Scharschmidt BF. Normal fasting-state levels of serum cholyl-conjugated bile acids in Gilbert's syndrome: an aid to the diagnosis. Hepatology. 1982 May-Jun; 2(3):340-3. PMID: 7076117.
      View in: PubMed
    162. Vierling JM. Copper metabolism in primary biliary cirrhosis. Semin Liver Dis. 1981 Nov; 1(4):293-308. PMID: 7051310.
      View in: PubMed
    163. James SP, Vierling JM, Strober W. The role of the immune response in the pathogenesis of primary biliary cirrhosis. Semin Liver Dis. 1981 Nov; 1(4):322-37. PMID: 7051311.
      View in: PubMed
    164. Berk PD, Berman MD, Blitzer BL, Chretien P, Martin JF, Scharschmidt BF, Vierling JM, Wolkoff AW, Vergalla J, Waggoner JG. Effect of splenectomy of hepatic bilirubin clearance in patients with hereditary spherocytosis. Implications for the diagnosis of Gilbert's syndrome. J Lab Clin Med. 1981 Jul; 98(1):37-45. PMID: 7252326.
      View in: PubMed
    165. Steer CJ, James SP, Vierling JM, Hosea SW, Jones EA. The selective hepatic uptake of desialylated peripheral blood mononuclear cells in rabbits. Gastroenterology. 1980 Nov; 79(5 Pt 1):917-23. PMID: 7419016.
      View in: PubMed
    166. Jones EA, Vierling JM, Steer CJ, Reichen J. Cell surface receptors in the liver. Prog Liver Dis. 1979; 6:43-80. PMID: 396566.
      View in: PubMed
    167. Jaffe CJ, Vierling JM, Jones EA, Lawley TJ, Frank MM. Receptor specific clearance by the reticuloendothelial system in chronic liver diseases. Demonstration of defective C3b-specific clearance in primary biliary cirrhosis. J Clin Invest. 1978 Nov; 62(5):1069-77. PMID: 711852; PMCID: PMC371867.
    168. Vierling JM, Steer CJ, Hickman JW, James SP, Jones EA. Cell-mediated cytotoxicity of desialylated human lymphocytes induced by a mitogenic mammalian liver protein. Gastroenterology. 1978 Sep; 75(3):456-61. PMID: 680501.
      View in: PubMed
    169. Jones EA, Vergalla J, Steer CJ, Bradley-Moore PR, Vierling JM. Metabolism of intact and desialylated alpha 1-antitrypsin. Clin Sci Mol Med. 1978 Aug; 55(2):139-48. PMID: 307998.
      View in: PubMed
    170. Vierling JM, Shrager R, Rumble WF, Aamodt R, Berman MD, Jones EA. Incorporation of radiocopper into ceruloplasmin in normal subjects and in patients with primary biliary cirrhosis and Wilson's disease. Gastroenterology. 1978 Apr; 74(4):652-60. PMID: 631501.
      View in: PubMed
    171. Vierling JM, Steer CJ, Bundy BM, Strober W, Jones EA, Hague NE, Nelson DL. Studies of complement receptors on cytotoxic effector cells in human peripheral blood. Cell Immunol. 1978 Feb; 35(2):403-13. PMID: 620434.
      View in: PubMed
    172. Vierling JM, Nelson DL, Strober W, Bundy DM, Jones EA. In vitro cell-mediated cytotoxicity in primary biliary cirrhosis and chronic hepatitis. Dysfunction of spontaneous cell-mediated cytotoxicity in primary biliary cirrhosis. J Clin Invest. 1977 Nov; 60(5):1116-28. PMID: 332716; PMCID: PMC372464.
    173. Martin JF, Vierling JM, Wolkoff AW, Scharschmidt BF, Vergalla J, Waggoner JG, Berk PD. Abnormal hepatic transport of indocyanine green in Gilbert's syndrome. Gastroenterology. 1976 Mar; 70(3):385-91. PMID: 814028.
      View in: PubMed
    174. Gardner KD, Vierling JM. Solids, water, and solutes in papillary region of the rat kidney. Am J Physiol. 1969 Jul; 217(1):58-64. PMID: 5785900.
      View in: PubMed
    175. Vierling J, Roberts JL, Conway G, Heazlitt R. Effect on cardiac myosin of diverse methods of preparation. Biochim Biophys Acta. 1968 May 6; 160(1):53-62. PMID: 4231409.
      View in: PubMed
    VIERLING's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description
    Physical Neighbors Expand Description
    _